Medical oxygen innovation landscape
Women’s and children’s health
Unitaid audited financial report for the year ended 31 December 2023
The untold story of dolutegravir: When climate impact goes hand-in-hand with access to better treatments
Antimalarial manufacturing in Africa: A call for regional action
Unitaid’s climate and health strategy 2023-2027
Unitaid’s investment case 2023-2027, executive summary
Unitaid’s investment case 2023-2027
Unitaid Strategy 2023-2027
Maternal and newborn health
Women’s and children’s health
Global malaria diagnostic and artemisinin treatment commodities demand forecast: 2017 – 2021 Report (May 2018)
Fever Diagnostic Technology Landscape
Multi-disease diagnostics landscape for integrated management of HIV, HCV, TB and other coinfections
Hepatitis C medicines technology and market landscape
Unitaid’s approach to intellectual property
Discussion Paper: Ensuring that essential medicines are also affordable medicines: challenges and options
Discussion Paper: An economic perspective on delinking the cost of R&D from the price of medicines
Unitaid and the Government of Spain
About Unitaid (Saving lives faster)
Unitaid and the UK Government
Unitaid audited financial report for the year ended 31 December 2023
Partnership report: Unitaid and the Global Fund to Fight AIDS, Tuberculosis and Malaria
Unitaid audited financial report for the year ended 31 December 2022
Unitaid audited financial report for the year ended 31 December 2014
Malaria vector control commodities landscape – 2nd edition
HIV preventives technology and market landscape – 2nd edition
Tuberculosis medicines technology and market landscape – 2nd edition
Tuberculosis diagnostics technology and market landscape – 3rd edition
Guideline for project implementers on Unitaid requirements for quality assurance of health products
Procurement of health products: An operational guideline for Unitaid grantees
Malaria diagnostics technology and market landscape – 2nd edition
